Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Pathology

Grading, staging papillary urothelial carcinoma

July 2026—Grading of papillary urothelial carcinoma can sometimes be challenging because it requires categorizing discretely a continuous spectrum of tumors. In the view of Lara Harik, MD, discovering biomarkers that can predict progression would be an ideal solution for papillary urothelial carcinoma, especially for tumors that are difficult to grade. “Maybe the use of cell-free DNA in the near future,” she said, “could reveal which of these tumors are at risk for progression.”

IHC workup of lung neuroendocrine neoplasms

June 2026—The immunostaining landscape for lung neuroendocrine tumors continues to evolve, and Humberto Trejo Bittar, MD, in a CAP25 lung cancer session last fall, captured where it stands.

ASCO to shine light on multimodal AI models:
Plus, melanoma diagnostics and gastroesophageal cancer targets

April 2026—Artificial intelligence, circulating tumor DNA, trial data: ASCO 2026 next month in Chicago will feature platforms, technologies, and therapeutic approaches once considered future concepts in cancer diagnosis and care. What comes now is less flashy than a breakthrough advance perhaps, but no less significant. As Janice Lu, MD, PhD, puts it, “The real work now is disciplined clinical translation: validation, collaboration, and implementation, in ways that truly improve patient care.”

At USCAP, a close look at GI biomarkers

February 2026—At the USCAP 2026 meeting, two guidelines on gastrointestinal pathology biomarkers will be presented. The updated guideline on HER2 testing in gastroesophageal adenocarcinoma reaffirms IHC with follow-up ISH as the best method for …

How to validate pan-HER2 immunohistochemistry

January 2026—Based on the results of Destiny-PanTumor02,1 targeted HER2-based therapies are now available as treatment options agnostic of tumor type. As oncologists seek to offer these targeted therapies to the patients likely to benefit, many laboratories have had to determine how best to expand the use of existing HER2 assays. At the same time, other laboratories may now see testing volumes increasing to justify new validation.

Slide, tissue block repository ties past to AI’s future

September 2025—The largest repository of pathology slides and tissue blocks is becoming a powerful data repository with the promise to transform diagnosis and treatment through the use of artificial intelligence. When U.S. military operations of all kinds were slashed or shuttered in 2008 under the Base Realignment and Closure federal initiative, a massive U.S. Army repository of slides and tissue blocks—including gross specimens dating back to the Civil War—came close to being one of the victims. It was housed at the Armed Forces Institute of Pathology, which had been targeted for closure. “When BRAC happened, and all of these Department of Defense facilities were closed, they didn’t know what to do with their pathology tissues,” says Mark D. Lyman, MD, Colonel, Medical Corps, U.S. Air Force, and director of the Joint Pathology Center (JPC), Silver Spring, Md. “There was even some discussion about throwing the repository away.”

How far? How much? What labs say about digital path

October 2025—Glass or digital, onsite or remote—and what the rules are for the latter. That’s what Compass Group lab leaders talked about with CAP TODAY publisher Bob McGonnagle when they met online on Sept. 2. Here’s a glimpse into their digital pathology journeys. The Compass Group is an organization of not-for-profit IDN system laboratory leaders who collaborate to identify and share best practices and strategies.

MARKETPLACE

TRENDING